The pharmaceutical industry may be on the brink of a transformation, with innovative “robot pills” offering a potential solution for drug delivery, which could also prove lucrative for investors. This revelation comes despite the stocks’ current undervalued status and associated risks, CNBC reported.
Some early-stage drug delivery companies are developing pills that can safely transport delicate molecules through the harsh conditions of the gastrointestinal tract. These companies, largely unnoticed by investors, could be the next big thing in the pharmaceutical industry.
Edward Nash, an analyst at Canaccord Genuity, explains that drug delivery has traditionally been a roll-up sector.
“Once they really started to show positive proof of concept data, you would see Big Pharma … swoop in and take them over,” he said.
Companies such as Rani Therapeutics (NASDAQ:RANI), Biora Therapeutics (NASDAQ:BIOR), Avalyn Pharma and Elektrofi are making strides in this area.
Both Rani and Biora are employing capsules, or “robot pills”, in their drug delivery systems. These capsules protect the drug until ...